1. Introduction {#sec1-jcm-08-01842}
===============

Graves' disease (GD) is an autoimmune inflammatory disease. The annual incidence of Graves' disease is 20 to 50 cases per 100,000 persons \[[@B1-jcm-08-01842]\]. Graves' ophthalmopathy (GO) also called thyroid eye disease occurs in 25--50% of patients suffered from GD \[[@B2-jcm-08-01842]\]. The reported prevalence rates of Graves' ophthalmopathy among different ethnic populations are limited. An early study demonstrated 6.4 times higher risk of developing GO in Caucasians than that of Asians \[[@B3-jcm-08-01842]\] but has been criticized for a small sample size. Recent studies reported similar prevalence rate in Malaysians (Malay, Chinese, and Indian) \[[@B4-jcm-08-01842]\] and Indians \[[@B5-jcm-08-01842]\] with GD as compared with Caucasian GD patients. The clinical presentation of GO includes eyelid retraction, restrictive extraocular myopathy, proptosis, glaucoma, exposure keratitis and compressive optic neuropathy \[[@B6-jcm-08-01842]\]. Patients may experience frequent diplopia, dry eye, chemosis, eyelid swelling and even vision loss in severe cases \[[@B7-jcm-08-01842]\]. Additionally, patients with Graves' disease tend to have concomitant hyperthyroidism.

Genetic analysis has identified several susceptible genes, including genes encoding thyroglobulin, thyrotropin receptor, HLA-DRβ-Arg74, protein tyrosine phosphatase nonreceptor type 22 (PTPN22), cytotoxic T-lymphocyte--associated antigen 4 (CTLA4), CD25, and CD40 \[[@B8-jcm-08-01842]\]. Recent studies have identified circulating autoantibodies which target the thyroid-stimulating hormone receptor and insulin-like growth factor-1 receptor on the orbital fibroblasts \[[@B9-jcm-08-01842],[@B10-jcm-08-01842]\]. Further activation of inflammatory genes leads to overproduction of cytokines, chemoattractants, hyaluronan and glycosaminoglycan, which results in orbital inflammation in the early phase and tissue hypertrophy in the late phase \[[@B11-jcm-08-01842]\]. The expression level of these gene associated with GD and inflammation would different according to their genotype, and further study on genetic polymorphism in these genes would predict prognosis or complications in GD patients.

Treatment of GO varies according to the disease severity \[[@B12-jcm-08-01842]\]. Establishing a euthyroid state and quitting smoking are helpful \[[@B13-jcm-08-01842]\]. Active inflammatory phase often requires corticosteroids or other immunosuppressants to reduce orbital congestion \[[@B14-jcm-08-01842]\]. Early intervention and close monitoring may hamper the progression and the severity of the disease \[[@B15-jcm-08-01842]\]. It would be beneficial to find biomarkers early predicting severe GO in GD patients. Herein, all regions of CTLA4 including promoter, exon and 3′UTR were investigated to find the correlation of CTLA4 gene polymorphism and GO.

2. Experimental Section {#sec2-jcm-08-01842}
=======================

2.1. Study Subjects {#sec2dot1-jcm-08-01842}
-------------------

Twenty-two patients with GO (46.2 ± 16.5 years old, eight males and fourteen females) and 20 healthy controls (28.3 years old, 5 males and 15 females) were included in Linkou Chang Gung Memorial Hospital during the period from June 2017 to May 2019.

2.2. DNA Extraction {#sec2dot2-jcm-08-01842}
-------------------

The blood samples were collected in EDTA-coated vacuum tubes. The genomic DNA was extracted using QIAamp^®^ DNA Mini kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer's instructions. DNA concentration and purity were evaluated by measuring the optical density at 260 and 280 nm through UV spectrometer.

2.3. PCR Amplification {#sec2dot3-jcm-08-01842}
----------------------

The PCR mixture contained 1 µL DNA, 10µL HotStarTaq DNA Polymerase (Qiagen GmbH, Hilden, Germany), 1 µL forward primer (10 µM), 1 µL reverse primer (10 µM) and 12 µL ddH~2~O. [Table 1](#jcm-08-01842-t001){ref-type="table"} displayed the primers used in the present study. The PCR program for promoter and exon 1 was 1 cycle 95 °C for 10 min, 35 cycles of 94 °C for 30 sec, 65.5 °C for 30 sec, and 72 °C for 1 min. The PCR program for exon 2, exon 3, exon 4, and 3′UTR was 1 cycle 95 °C for 10 min, 35 cycles of 94 °C for 30 s, 59 °C for 30 s, and 72 °C for 1 min. The final elongation step was 3 min at 72 °C and then soaking at 10 °C. For gel electrophoresis visualization, 5 μL of the PCR products was pipetted onto a 1.5% agarose gel and run at 100 V for 20 min. Correct PCR products were visualized under UV illumination.

2.4. Purifying and Sequencing {#sec2dot4-jcm-08-01842}
-----------------------------

The PCR production was purified by mixture containing 2.5 µL shrimp alkaline phosphatase and 0.05 µL exonuclease I (New England Biolabs, UK), and the purified PCR products were sequenced using ABI PRISM 3730 DNA Analyzer (Applied Biosystems, Foster City, CA, USA). Single nucleotide polymorphisms (SNPs) analysis were performed on CTLA4 gene, and rs11571315, rs733618, rs4553808, rs11571316, rs62182595, rs16840252, rs5742909, rs231775, and rs3087243 were selected for genotyping.

2.5. Statistical Analysis {#sec2dot5-jcm-08-01842}
-------------------------

All statistical data analyses were performed by the SPSS 17.0. Genotype and allele frequencies of CTLA4 gene for patients with GO were compared to healthy controls. Chi-square or Fisher's exact test were used to evaluate the association between GO and CTLA4 SNPs.

3. Results {#sec3-jcm-08-01842}
==========

Among 22 GO patients, there were 14 females and 8 males, and the average age of patients was 46 years old. Moreover, half of GO patients was moderate in severity categories \[[@B16-jcm-08-01842]\], and the most common symptom of GO patients was proptosis. The characteristics of patients were shown in [Table 2](#jcm-08-01842-t002){ref-type="table"}.

The severity of GO was classified via the criterion proposed by Werner \[[@B6-jcm-08-01842]\]. Class 0 to class 2 were classified as "mild", class 3 and class 4 were classified as "moderate", class 5 and class 6 were classified as "severe".

All SNPs were in accordance with the Hardy-Weinberg equilibrium in the control group (*p* \> 0.05) ([Table 3](#jcm-08-01842-t003){ref-type="table"}). There was no nucleotide substitution in exon 2 and exon 3 of CTLA4 region, and the allele frequencies of CTLA4 polymorphisms had no significant difference between patients with GO and controls. However, the genotype frequency ([Table 4](#jcm-08-01842-t004){ref-type="table"}) of "TT" genotype in rs733618 significantly differed between patients with GO and healthy controls (OR = 0.421, 95%CI: 0.290--0.611, *p* = 0.043), and the "CC" and "CT" genotype in rs16840252 were nearly significantly differed in genotype frequency (*p* = 0.052). Haplotype analysis ([Table 5](#jcm-08-01842-t005){ref-type="table"}) showed that CTLA4 Crs733618Crs16840252 might increase the risk of GO (OR = 2.375, 95%CI: 1.636-3.448, *p* = 0.043).

Our data suggested that the genotype of −1722 (rs733618) in the promoter region of CTLA4 was associated with GO, the p value of TT vs. (CT + CC) was 0.043. We further combined −1722 (rs733618) and −1147 (rs16840252) together to observe the correlation between GO and controls, because the genotype of −1147 was very close to the critical point, *p* = 0.052. As a result, the two-marker combination was found to be more significantly related to GO (*p* = 0.025).

4. Discussion {#sec4-jcm-08-01842}
=============

Previous research had found that rs733618 \[[@B17-jcm-08-01842]\], rs231775 \[[@B17-jcm-08-01842]\], rs3087243 \[[@B18-jcm-08-01842],[@B19-jcm-08-01842]\] and a two-marker combination containing rs733618 and rs16840252 \[[@B17-jcm-08-01842]\] were related to GD. Our results showed that rs733618 was specifically related to GO. Comparing family-based research \[[@B17-jcm-08-01842]\] to our results, only rs733618 in promoter was related to GO but not rs231775 in exon 1, and it indicated that major transcription level of CTLA4 was affected by SNPs in promoter region. Moreover, SNPs in exon 1 did not lead to significant reduced protein expression \[[@B20-jcm-08-01842]\]. Therefore, rs733618 were associated with GD and GO, and "TT" genotype of rs733618 which was found to increasing the risk of GO in our study may affect major transcription level of CTLA4.

W. Tang et al., used expectation-maximization (EM) algorithm to create several feasible haplotypes, and haplotype compounded of Grs733618Crs16840252Ars231775Grs3087243 was associated with gastric cardia adenocarcinoma (*p* = 0.012) \[[@B21-jcm-08-01842]\]. Our results indicated that Crs733618Crs16840252 was related to GO. Therefore, these two SNPs might be involved in both cancer and autoimmune disease. The immune dysfunction would be affected by CTLA4 genetic variation, and the risk of cancer and the development of autoimmune disease would be increased \[[@B22-jcm-08-01842]\]. The rs16840252 mutation would increase the risk of cancer as well \[[@B23-jcm-08-01842]\]. The most central function of CTLA4 is negative regulation of T cell activation, and it is expressed on the surface of activated T cells and competes to B7 with CD28 \[[@B24-jcm-08-01842],[@B25-jcm-08-01842]\]. On the contrary, autoimmune disease would develop by reducing CTLA4 transcription level because of the immune responses are overreacting \[[@B26-jcm-08-01842]\]. Investigation of rs733618 and rs16840252 in T cell activation would uncover the underlying mechanism in development of GO. In [Table 6](#jcm-08-01842-t006){ref-type="table"}, disease association of rs733618 \[[@B23-jcm-08-01842],[@B27-jcm-08-01842],[@B28-jcm-08-01842],[@B29-jcm-08-01842],[@B30-jcm-08-01842],[@B31-jcm-08-01842],[@B32-jcm-08-01842],[@B33-jcm-08-01842],[@B34-jcm-08-01842]\] and rs16840252 \[[@B35-jcm-08-01842],[@B36-jcm-08-01842]\] were summarized.

Several studies in GD-related CTLA4 SNPs were summarized in [Table 7](#jcm-08-01842-t007){ref-type="table"}. We found that those GD-related SNPs were located at different positions in the CTLA4 region within different populations. The majority of patients with GD from different ethnicities were associated with rs231775 and/or rs3087243 (Polish \[[@B37-jcm-08-01842],[@B38-jcm-08-01842]\], Chinese \[[@B39-jcm-08-01842],[@B40-jcm-08-01842],[@B41-jcm-08-01842],[@B42-jcm-08-01842],[@B43-jcm-08-01842],[@B44-jcm-08-01842]\], Saudi Arabian \[[@B45-jcm-08-01842],[@B46-jcm-08-01842]\], Iranian \[[@B47-jcm-08-01842],[@B48-jcm-08-01842]\], Italian \[[@B49-jcm-08-01842]\], Japanese \[[@B50-jcm-08-01842]\], and Taiwanese \[[@B17-jcm-08-01842],[@B18-jcm-08-01842],[@B19-jcm-08-01842]\]). However, rs733618 and its relationship with GO have been found merely in Taiwan population. Thus, the correlation between GO and SNPs would diversely result from racial specificity, severity of GO and various inclusion criteria. Further investigation on racial specific GD-related SNPs associated with GO would be indicated.

Herein, Crs733618Crs16840252 of the CTLA4 promoter was shown to be associated with increasing risk of GO. Promoter polymorphism can influence gene transcription, as well as the disease severity \[[@B53-jcm-08-01842]\]. The signal peptide is encoded by exon 1, and mutations in this exon suppress CTLA-4 protein expression \[[@B54-jcm-08-01842]\]. Regulation of mRNA-based processes, such as mRNA localization, mRNA stability, translation, as well as regulation of protein features not encoded in the amino acid sequence are most commonly regulated by 3′UTR \[[@B55-jcm-08-01842]\]. Consequently, there would be other significant SNPs located including but not limited to promoter region associated with GO. Further clinical application for prediction of GO in GD patients needs a feasibility study, and investigation of the mechanism of CTLA4 SNPs and haplotype of GO should be performed.

5. Conclusions {#sec5-jcm-08-01842}
==============

In conclusion, CTLA4 Crs733618Crs16840252 was found to be a potential marker for GO, and these haplotypes would be ethnicity-specific. Clinical application of CTLA4 Crs733618Crs16840252 in predicting GO in GD patients may be beneficial.
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jcm-08-01842-t001_Table 1

###### 

Primers used for CTLA4 in this study.

  ------------------------------------------------------------------------------------
  Primer                                          GC Content     Tm (°C)   Base Pair
  ----------------------------------------------- -------------- --------- -----------
  promotor and exon1                                                       

  F: 5′ GGC AAC AGA GAC CCC ACC GTT 3′\           21/13 (62%)\   65.3\     1234
  R: 5′ GAG GAC CTT CCT TAA ATC TGG AGA G 3′      25/12 (48%)    65.8      

  F: 5′ CTC TCC AGA TTT AAG GAA GGT CCT C 3′\     25/12 (48%)    65.8      1170
  R: 5′ GGA ATA CAG AGC CAG CCA AGC C 3′                                   

  22/13 (59%)                                     65.8                     

  Exon2 and exon3                                                          

  F: 5′ CAT GAG TTC ACT GAG TTC CC 3′\            20/10 (50%)    58.4 °C   1034
  R: 5′ TAC CAC TGT CCT TCC TCT TC 3′                                      

  20/10 (50%)                                     58.4 °C                  

  Exon4                                                                    

  F: 5′ CTA GGG ACC CAA TAT GTG TTG 3′\           21/10 (48%)    59.5      360
  R: 5′ AGA AAC ATC CCA GCT CTG TC 3                                       

  20/10 (50%)                                     58.4                     

  3′UTR                                                                    

  F1: 5′ CAG CTA GGG ACC CAA TAT GTG TTG AG 3′\   26/13 (50%)    59.5      1088
  R1: 5′ GTC AAG TCA ACT CAG ATA CCA CCA GC 3′\                            
  F2: 5′ GCT TGG AAA CTG GAT GAG GTC ATA GC 3′\                            
  R2: 5′ AGA GGA AGA GAC ACA GAC AGA GTT GC 3′                             

  26/13 (50%)                                     59.5                     

  26/13 (50%)                                     59.5           1255      

  26/13 (50%)                                     59.5                     
  ------------------------------------------------------------------------------------

F: forward primer; R: reverse primer.

jcm-08-01842-t002_Table 2

###### 

Characteristics of patients (*n* = 22).

                               Total, No. (%)
  ---------------------------- ----------------
  Median age of the patients   46.2 ± 16.5
  Sex of the patients          
  Male                         8 (36.4)
  Female                       14 (63.6)
  Graves' ophthalmopathy       
  Mild                         7 (31.8)
  Moderate                     14 (63.6)
  Severe                       1 (4.6)

jcm-08-01842-t003_Table 3

###### 

Allele frequencies in patients and controls and odds ratio of developing Graves' ophthalmopathy.

  SNP          Position    Allele   Minor Allele Frequency   HWE *p* Value   Odds Ratio   χ^2^ *p* Value          
  ------------ ----------- -------- ------------------------ --------------- ------------ ----------------------- -------
  rs11571315   203866178   C/T      0.181                    0.275           0.237        1.707 (0.607--4.799)    0.308
  rs733618     203866221   T/C      0.409                    0.500           0.670        1.444 (0.609--3.425)    0.403
  rs4553808    203866282   A/G      0.068                    0.175           0.638        2.899 (0.695--12.091)   0.182
  rs11571316   203866366   A/G      0.114                    0.100           0.884        1.154 (0.287--4.635)    1
  rs62182595   203866465   A/G      0.068                    0.175           0.638        2.899 (0.695--12.091)   0.182
  rs16840252   203866796   C/T      0.068                    0.200           0.535        3.417 (0.838--13.927)   0.074
  rs5742909    203867624   C/T      0.068                    0.175           0.638        2.899 (0.695--12.091)   0.182
  rs231775     203867991   A/G      0.182                    0.275           0.237        1.707 (0.607--4.799)    0.308
  rs3087243    203874196   A/G      0.114                    0.100           0.884        1.154 (0.287--4.635)    1

HWE: Hardy-Weinberg equilibrium; 95%CI: 95% confidence interval.

jcm-08-01842-t004_Table 4

###### 

Statistical analysis of CTLA4 (SNPs).

  SNP          Genotype   Genotype Frequency   Odds Ratio (95 % CI)    *p* Value               
  ------------ ---------- -------------------- ----------------------- ----------------------- --------------------
  rs11571315   CC         0                    0                       NA                      NA
  CT           8          11                   0.468 (0.136--1.611)    *p* = 0.226             
  TT           14         9                    2.139 (0.621--7.370)    *p* = 0.226             
  rs733618     CC         4                    4                       0.889 (0.190--4.150)    *p* = 1
  CT           18         12                   3.000 (0.736--12.227)   *p* = 0.118             
  TT           0          4                    0.421 (0.290--0.611)    *p* = 0.043 **\*\***    
  rs4553808    AA         19                   13                      3.410 (0.742--15.677)   *p* = 0.152
  AG           3          7                    0.293 (0.064--1.348)    *p* = 0.152             
  GG           0          0                    NA                      NA                      
  rs11571316   AA         0                    0                       NA                      NA
  AG           5          4                    1.176 (0.267--5.176)    *p* = 1                 
  GG           17         16                   0.850 (0.193--3.739)    *p* =1                  
  rs62182595   AA         0                    0                       NA                      NA
  AG           3          7                    0.293 (0.064--1.348)    *p* = 0.152             
  GG           19         13                   3.410 (0.742--15.677)   *p* = 0.152             
  rs16840252   CC         19                   12                      1.22 (0.932--19.131)    *p* = 0.052 **\***
  CT           3          8                    0.237 (0.052--1.073)    *p* = 0.052 **\***      
  TT           0          0                    NA                      NA                      
  rs5742909    CC         19                   13                      3.410 (0.742--15.677)   *p* = 0.152
  CT           3          7                    0.293 (0.064--1.348)    *p* = 0.152             
  TT           0          0                    NA                      NA                      
  rs231775     AA         0                    0                       NA                      NA
  AG           8          11                   0.468 (0.136--1.611)    *p* = 0.226             
  GG           14         9                    2.139 (0.621--7.370)    *p* = 0.226             
  rs3087243    AA         0                    0                       NA                      NA
  AG           5          4                    1.250 (0.283--5.525)    *p* = 1                 
  GG           17         16                   0.800 (0.181--3.536)    *p* = 1                 

95%CI: 95% confidence interval; NA: Not applicable. \* indicates *p* \< 0.1, \*\* indicates *p* \< 0.05.

jcm-08-01842-t005_Table 5

###### 

*CTLA4* haplotypes and odds ratio of developing Graves' ophthalmopathy.

  CTLA4 Haplotypes           Patient(n)   Control (n)   OR (95%CI)             *p* Value
  -------------------------- ------------ ------------- ---------------------- ----------------
  C~rs733618~C~rs16840252~   22           16            2.375 (1.636--3.448)   0.043 **\*\***
  C~rs733618~T~rs16840252~   3            5             0.474 (0.097--2.307)   0.445
  T~rs733618~C~rs16840252~   18           16            1.125 (0.241--5.252)   1
  T~rs733618~T~rs16840252~   3            7             0.293 (0.064--1.348)   0.152

OR: odds ratio; 95%CI: 95% confidence interval; NA: Not applicable. \*\* indicates *p* \< 0.05.

jcm-08-01842-t006_Table 6

###### 

Summary of rs733618 and rs16840252-related disease.

  SNP          Disease                                                                          Subjects and Results                                                                                                                                                                                                Ref.
  ------------ -------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------
  rs733618     Systemic lupus                                                                   Asian:                                                                                                                                                                                                              \[[@B23-jcm-08-01842]\]
               erythematosus                                                                    C allele was strongly associated with SLE and also CC genotype was significantly associated with the risk of SLE, *p* = 0.000).                                                                                     
               Breast cancer                                                                    Chinese:                                                                                                                                                                                                            \[[@B27-jcm-08-01842]\]
                                                                                                CC genotype and C allele showed an increased risk of breast cancer (*p* = 0.030, odds ratio (OR) = 1.457, 95% confidence internal (CI) 1.036--2.051; *p* = 0.024, OR = 1.214, 95% CI 1.026--1.436, respectively).   
               Polycystic ovary syndrome                                                        Chinese Han population:                                                                                                                                                                                             \[[@B28-jcm-08-01842]\]
                                                                                                significantly different between case and control groups in either genotypic or allelic distribution, *p* = 0.01 and 0.009, respectively.                                                                            
               Survival in patients with sepsis                                                 Adult Caucasian patients with sepsis:                                                                                                                                                                               \[[@B29-jcm-08-01842]\]
                                                                                                lower 90-day mortality was observed for T~rs733618~ A~rs231775~ A~rs3087243~ haplotype-negative patients than for patients carrying the TAA haplotype, *p* = 0.0265.                                                
               Survival in patients with multiple myeloma receiving bortezomib-based regimens   Unrelated Chinese Han population: GG genotype reduced the progression-free survival and the overall survival of patients with multiple myeloma who received bortezomib-based therapy, *p* = 0.002.                  \[[@B30-jcm-08-01842]\]
               Non-small-cell lung cancer                                                       Chinese:                                                                                                                                                                                                            \[[@B31-jcm-08-01842]\]
               (NSCLC)                                                                          T \> C polymorphism was associated with the development of NSCLC in ≥60 years and even drinking subgroups.                                                                                                          
               Myasthenia gravis (MG)                                                           Chinese Han population:                                                                                                                                                                                             \[[@B32-jcm-08-01842]\]
                                                                                                C allele were more frequent in MG patients, *p* = 0.042.                                                                                                                                                            
               Urinary schistosomiasis                                                          Gabonese children:                                                                                                                                                                                                  \[[@B33-jcm-08-01842]\]
                                                                                                T allele and TT genotype were significantly overrepresented in the patient group, *p* = 0.001.                                                                                                                      
               Lymphatic filariasis (LF)                                                        Sarawak, Malaysia:                                                                                                                                                                                                  \[[@B34-jcm-08-01842]\]
                                                                                                CT genotype (*p* = 0.02) and those with combined minor allele C carriers (CT + CC; *p* = 0.01) exhibited a significantly decreased risk for LF.                                                                     
  rs16840252   Colorectal cancer                                                                Chinese:                                                                                                                                                                                                            \[[@B35-jcm-08-01842]\]
                                                                                                polymorphism was associated with an increased risk of colon cancer in homozygote model *p* = 0.040 and recessive model *p* = 0.037.                                                                                 
               Recurrent schizophrenia                                                          Chinese Han population:                                                                                                                                                                                             \[[@B36-jcm-08-01842]\]
                                                                                                A significant association with schizophrenia, *p* (allele) = 0.0081, *p* (genotype) = 0.0117.                                                                                                                       

jcm-08-01842-t007_Table 7

###### 

Summary of several studies for *CTLA4* SNPs associated with Graves' disease.

  SNP         Subjects                                       Results                                                                                                                                                                                                       Ref.
  ----------- ---------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------
  rs733617    Han population of Taiwan (family-based)        C allele over-transmitted to affected individuals (χ^2^ = 6.714, nominal *p* = 0.0096).                                                                                                                       \[[@B17-jcm-08-01842]\]
  rs5742909   Polish Caucasian                               genotype and allele were differentially distributed (*p* = 0.0002; *p* = 4.07 × 10^−5^), and lack of the rare T allele increased GD in patients with familial autoimmune thyroid incidence (*p* = 0.00005).   \[[@B37-jcm-08-01842]\]
              Chinese                                        genotype frequencies of CT and allele frequencies of T were much higher in GD patients with ophthalmopathy than that in the group without ophthalmopathy (*p* = 0.020, *p* = 0.019).                          \[[@B39-jcm-08-01842]\]
              Chinese                                        variant allele carriers might have decreased risks of GD when compared with the homozygote carriers TT + TC vs. CC: OR = 0.78, 95% CI = 0.62--0.97.                                                           \[[@B44-jcm-08-01842]\]
  rs231775    Han population of Taiwan (family-based)        CTLA4\_+49_G/A (*p* = 0.0219), with its minor allele (G allele) over-transmitted to affected individuals (χ^2^ = 5.252, nominal *p* = 0.0219).                                                                \[[@B17-jcm-08-01842]\]
              Taiwanese                                      significant differences in the frequencies of the genotypes and alleles, *p* \< 0.05.                                                                                                                         \[[@B18-jcm-08-01842]\]
              Polish populations                             a significantly lower frequency of the AA genotype in the group of patients with clinically evident GO (*p* = 0.02, OR = 2.6).                                                                                \[[@B38-jcm-08-01842]\]
              Chinese                                        genotype GG and allele frequencies of G in patients with Graves' disease were significantly increased as compared with control group (*p* = 0.008, *p* = 0.007).                                              \[[@B39-jcm-08-01842]\]
              Han population of Chinese (unrelated)          allele G was significantly associated with GD in adults (*p* \< 0.001) and children (*p* = 0.002)).                                                                                                           \[[@B40-jcm-08-01842]\]
              Chinese children \< 16 years old (unrelated)   genotype GG (*p* = 0.005) and allele G (*p* = 0.03) were more prevalent in GD.                                                                                                                                \[[@B41-jcm-08-01842]\]
              Chinese children                               genotype and allele frequencies of children with GD differed significantly from those of the controls (*p* = 0.0023 and *p* = 0.022, respectively).                                                           \[[@B42-jcm-08-01842]\]
              Saudi Arabian                                  G allele was more frequent in patients with GD than in the control group, *p* = 0.003.                                                                                                                        \[[@B45-jcm-08-01842]\]
              Iranian                                        G allele was significantly higher in patients with Graves' disease than in the control group (27.1% vs. 15.1%, OR = 2.096, 95%CI = 1.350--3.253 and *p* \< 0.01).                                             \[[@B47-jcm-08-01842]\]
              Iranian                                        a significant increase of GG genotype and G allele was observed in patients (*p* = 0.012 and *p* = 0.025, respectively).                                                                                      \[[@B48-jcm-08-01842]\]
              Italian                                        G allele frequency was significantly higher compared to control subjects (*p* = 0.04).                                                                                                                        \[[@B49-jcm-08-01842]\]
              Caucasian and Asian                            G allele vs. A allele, *p* \< 0.00001; genotype: GG vs. AG + AA, *P* \< 0.00001; GG + AG vs. AA, *p* \< 0.00001; GG vs. AA, *p* \< 0.00001; AG vs. AA, *p* \< 0.00001.                                        \[[@B50-jcm-08-01842]\]
  rs3087243   Taiwanese children                             genotype GG was significantly associated with GD (OR = 1.71, 95% CI 1.20--2.44, *p* = 0.006); Allele G was significantly more frequent (OR = 1.61, 95% CI 1.18--2.19, *p* = 0.0049).                          \[[@B19-jcm-08-01842]\]
              Taiwanese                                      G allele is associated with susceptibility to Graves' disease (*p* = 0.011).                                                                                                                                  \[[@B18-jcm-08-01842]\]
              Han population of Chinese (unrelated)          allele G was significantly associated with GD in adults (*p* \< 0.001) and children (*p* \< 0.001).                                                                                                           \[[@B40-jcm-08-01842]\]
              Chinese children \< 16 years old (unrelated)   G allele was more prevalent in GD *p* = 0.02.                                                                                                                                                                 \[[@B41-jcm-08-01842]\]
              Southern China                                 G allele was significantly associated with an increased risk of GD development, *p* \< 0.001.                                                                                                                 \[[@B43-jcm-08-01842]\]
              Chinese                                        G \> A allele frequencies between the patient and control groups, *p* = 0.014.                                                                                                                                \[[@B44-jcm-08-01842]\]
              Russian                                        A allele and the AA genotypes were significantly increased in patients with GD.                                                                                                                               \[[@B45-jcm-08-01842]\]
              Saudi Arabian                                  G allele was higher in GD patients than those in controls, *p* = 0.004.                                                                                                                                       \[[@B46-jcm-08-01842]\]
              Italian                                        allelic frequency of the G allele was also significantly higher in patients with GD (*p* = 0.02).                                                                                                             \[[@B49-jcm-08-01842]\]
              Japanese                                       for the TBII-positive GD, G allele carriers in patients had significant association with GD, OR = 2.97, 95%CI = 1.29--6.87, *p* = 0.008.                                                                      \[[@B51-jcm-08-01842]\]
              Russian                                        significantly higher frequencies of A allele and AA genotype and a lower proportion of G allele and GG genotype.                                                                                              \[[@B52-jcm-08-01842]\]

[^1]: These authors contributed equally to this work.
